An Open-label, Single-sequence Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on the Pharmacokinetics of BMS-986165 in Healthy Participants
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Deucravacitinib (Primary) ; Ritonavir
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Liver disorders; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 21 Oct 2019 Status changed from recruiting to completed.
- 03 Sep 2019 Status changed from not yet recruiting to recruiting.
- 14 Aug 2019 New trial record